Abstract -While OLEDs have struggled to find a niche lighting application that can fully take advantage of their unique form factors as thin, flexible, lightweight and uniformly large-area luminaire, photomedical researchers have been in search of low-cost, effective illumination devices with such form factors that could facilitate widespread clinical applications of photodynamic therapy (PDT) or photobiomodulation (PBM). Although existing OLEDs with either fluorescent or phosphorescent emitters cannot achieve the required high power density at the right wavelength windows for photomedicine, the recently developed ultrabright and efficient deep red quantum dot light emitting devices (QLEDs) can nicely fit into this niche. Here, we report for the first time the in-vitro study to demonstrate that this QLED-based photomedical approach could increase cell metabolism over control systems for PBM and kill cancerous cells efficiently for PDT. The perspective of developing wavelength-specific, flexible QLEDs for two critical photomedical fields (wound repair and cancer treatment) will be presented with their potential impacts summarized. The work promises to generate flexible QLED-based light sources that could enable the widespread use and clinical acceptance of photomedical strategies including PDT and PBM.
Background for quantum dot light emitting devices and photomedicine
Photomedicine is an emerging medical field, in which light is used either to kill cancer cells with assistance of photosensitizers and singlet oxygen (photodynamic therapy, PDT) or to stimulate cellular function leading to beneficial clinical effects (photobiomodulation, PBM). They have been demonstrated as minimally invasive treatment strategies with expensive, bulky light sources, such as laser or LED arrays. 1 However, photomedicine still has not received widespread clinical acceptance mainly because of the lack of effective, low-cost illumination devices.
Because of their unique form factors as thin, flexible, lightweight and uniformly large-area light sources, organic light emitting devices (OLEDs) were once proposed to work as light-emitting bandages for PDT 2 but were later abandoned in favor of LEDs 3 because photomedical applications generally require light sources of relatively high brightness (>20 000 Cd/m 2 or~10 mW/cm 2 ) at wavelengths in the deep red region in order to have deep tissue penetration while still maintaining sufficient energy for molecular excitations. 1 Existing OLEDs with either fluorescent or phosphorescent emitters cannot achieve such high brightness at the right wavelength windows because of significant efficiency roll-off problems of OLEDs at high current density 4 and the lack of efficient deep red emitters with narrow spectra. 5 Thanks to their size-controlled tunable emission wavelength, narrow emission spectra and simple solution processability, quantum dot light emitting devices (QLEDs) have attracted much attention recently as a candidate for next generation display. 6 Among QLEDs of various colors, red QLEDs are currently most advanced and have demonstrated efficiency and brightness that rival or beat state-of-the-art thermal-evaporated red OLEDs, with narrow peak linewidths in the 20 to 30-nm range. In particular, our group has reported ultrabright and efficient deep red QLEDs. 7 As shown in Fig. 1 , the devices demonstrate peak emission wavelength of 620 nm, narrow bandwidth of 22 nm and can achieve high current efficiency (20.5 Cd/A at~20 000 Cd/m 2 ) and small efficiency roll-off at high driving current density. Ultrahigh brightness of 165 000 Cd/m 2 can be achieved at current density of 1000 mA/cm 2 , which sets a new brightness record for existing organic related red light emitting devices.
Although the relatively short lifetime of these ultrabright deep red QLED devices has limited their immediate applications in display or daily lighting markets, these ultrabright deep red QLED devices can be promising light sources for photomedicine where low-cost, wearable, disposable light emitting bandage products are highly desired. And the narrow emission band and wavelength tunability of QLEDs make it feasible to better fit the emission spectrum into the absorption window of photosensitizers (for PDT) or cytochrome C (for PBM).
In this paper, we present preliminary PBM and PDT results using these ultrabright red QLEDs as excitation light sources, with parallel studies using inorganic LEDs as comparisons. The perspective of tuning QLED wavelength for targeted photomedicine, development of flexible QLED and their potential impact to wound repair or cancer treatment will also be discussed.
Preliminary experimental results
A 4-pixel (4 × 4 mm each.) QLED array has been developed as photomedical light source. As shown in Fig. 2 , a specialized platform and cradle was built to stabilize the QLED array allowing proper tray positioning underneath cell cultures for in-vitro PBM and PDT experiments. The results are compared with control cell cultures that received no light treatment or parallel studies with inorganic LED treatment. were cultured in 24-well trays in complete Dulbecco's Modified Eagle Medium supplemented with 10% fetal bovine serum, streptomycin-penicillin-fungicin, glutamine and pyruvate, without phenol red. These cell lines are frequently used for in-vitro studies of PBM and are often used as surrogates for whole animal studies of wound healing, among other applications. HEp-2 cells are a human epithelial cell line derived from cervical cancer and are biologically identical to the famous HeLa cell line. The L929 is a mouse fibroblast cell line, and 3T3 cells are also a fibroblast cell type derived from mouse embryos.
Preliminary photobiomodulation results
Photoradiation was performed using the inverted ultrabright QLED to deliver 4.0 J/cm 2 to the culture wells during 10-min treatment at power density of~8 mW/cm 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay is a colorimetric assay and is a popular method to evaluate cell metabolic activity. Parallel studies were performed at 670 nm ± 20 nm using an LED device (Quantum Devices, Barneveld, WI) delivering 4.0 J/cm 2 during 10-min treatment for comparison with QLED PBM.
Assay results at 24 h (presented in Table 1) show that QLED PBM increased cell metabolism in the HEp-2 cell line and in a similar fashion to a NASA LED source. 8 For HEp-2, L929 and 3T3, QLED PBM increases the cell metabolism by 27.9, 26 and 12.5% over the control systems, respectively. Although the peak wavelength of QLED (~620 nm) is still away from the favorite 660 nm for PBM, the results of QLED BPM are comparable with the LED PBM. Further tuning the emission wavelength of QLED is expected to lead to improved PBM results.
Preliminary photodynamic therapy results
To evaluate the potential of red QLEDs as a light source for PDT, we used 3D cultures of A431 cells (a human cell line frequently used in cancer-associated biomedical study) grown on beds of laminin-rich-extracellular matrix and photosensitized by administration of aminolevulinic acid (ALA) leading to accumulation of protoporphyrin IX (PpIX) prior to light activation.
Cultures were treated using either the QLED sources with low average irradiance (approx 1.8 mW/cm LED). In the case of QLED irradiations, calibration runs were first performed to measure power drop off during extended continuous operation. Irradiation duration was determined by integration of irradiance over time to determine the time required (4.75 h) for the QLED to deliver the same total light dose as the solid state LED source (30 J/cm 2 ). Treatment response was evaluated 24 h after PDT using an imaging-based approach described previously. 9 As shown in Fig. 3 , both QLED and LED sources achieve photodestruction of 3D tumor nodules, while quantitative image processing of multiple replicates reveals PDT efficacy is slightly enhanced using the QLED source, with residual tumor viabilities of 0.61 +/À 0.04 versus 0.53 +/À 0.08 for the solid state and QLED sources respectively. This result is consistent with previous reports that PDT at low dose rates may be more effective and is significant here in view of the capability of the QLED to act as a low-cost, effective and ergonomic source for PDT light activation over extended periods.
These in-vitro studies are the first to demonstrate PBM and PDT using a QLED device and pave the way for further developments of QLED-based photomedicine.
Perspective

Wavelength tunable red QLED for targeted photomedicine
It should be noted that these promising preliminary results were obtained with ultrabright red QLED with a peak wavelength of~620 nm. While this wavelength falls into the favorite range for most photomedical applications (620-670 nm), highly effective phototherapy calls for better wavelength specific spectral control to maximize the absorption for photosensitizers (for PDT) or cytochrome C (for PBM) from QLED. By tuning the synthesis conditions (QDs size and composition), we can achieve ultrabright QLEDs with precisely controlled emission peaks at the following wavelengths for wound repair and cancer treatment applications (shown in Fig. 4 
Currently, such precise wavelength control can only be realized by expensive, bulky lasers, although the laser light needs to be waveguided with optical fibers and spread out with diffusers for large-area applications. Comparing to lasers, QLED has clear advantages as low-cost, large-area and wearable light sources.
Flexible QLED development
Flexible QLEDs are in obligatory demand to achieve a solution that is functional for a wearable bandage light source. While many groups have demonstrated their flexible devices by simply transferring the QLEDs from rigid substrates to flexible substrates, 10 much progress is still in need to further improve the device performance, reliability and to lower the manufacturing cost: 1) Transparent conductor material and process development: conventional QLED on rigid substrates uses indium tin oxide film as bottom conductor layer, which is not stable during repeated bending. Ag nanowire transparent conductor structure with superior surface planarity is more suitable for flexible QLEDs; 2) large-area printing of quantum dot for QLED: large-area printing of quantum dot is still at infancy state. Current lab scale printing using spin coating is not compatible with manufacturing. Electrospraying deposition would be developed for high uniformity; 3) thin film encapsulation for QLED: current thin film encapsulation for flexible OLED requires multiple layers to ensure reliability during cycle bending. By evaluating the requirement of water vapor transmission rate of QLED and developing rather simplified material and structure, flexible QLEDs could be more cost effective.
Photomedicine demonstration with rigid and flexible QLED devices
The preliminary PBM and PDT results will pave the way for applying the bright, pure color red QLEDs in rigid or flexible form factors to positively change phototherapy applications in dermatology, oncology, minimally invasive surgery, stroke and brain disease among other fields. In the following section, detailed discussions on two critical photomedical fields (wound repair and cancer treatments) will be provided based on medical expertise of the authors' teams. With 660-nm QLEDs, laboratories involved in PBM therapy would be able to investigate wound healing, cellular metabolism and cell proliferation in vitro using multiple cell lines and in animal models of incisional and pressure ulcer wounds. 11 The effect of spectral response, dosimetry and power density on the rate and quality of healing could be evaluated by histology, collagen content and other parameters. The results would be incorporated in future institutional review board-approved human clinical trials to achieve healing of chronic wounds or acceleration of healing of primary wounds using surgical incisions such as hernia incisions, C-sections or breast augmentations.
It had been discovered by Drs. Hamblin and Huang that PF can be transformed into highly effective light-activated antimicrobials by adding a harmless solution of potassium iodide (KI). The 630-nm QLEDs could be used in vitro to eradicate antibiotic resistant strains of Gram-positive, Gramnegative bacteria and fungi using mixtures of PF and KI. Researchers could also test QLEDs in combination with PF and KI in a mouse model of an infected abrasion wound caused by the bioluminescent drug-resistant pathogen, Acinenetobacter baumannii.
Laser-based PDT has previously been successfully transferred into the clinic in the treatment of head and neck and lung cancer by the Shafirstein laboratory with the computer-simulation-assisted optimization of light delivery and dosimetry. [12] [13] [14] [15] [16] Similar methods can be applied to model light propagation from QLEDs emitting 630, 635 and 665 nm for PDT with PF, 5-ALA and 2-1 [hexyloxyethyl]-2-devinylpyropheophorbide-A, respectively. In Fig. 5 , we present preliminary results from computer simulation of light propagation in a tissue mimicking geometry irradiated with 630-nm light wavelength delivered from a QLED with the model described previously in Oakley et al. 17 In this model, the light source was represented as a flux of photons emitted from the surface of the QLED. The resulting fluence rate (mW/cm 2 ) was computed throughout a cylindrical phantom, which mimicked the optical properties of tissue, when exposed to an input power density of 10 mW/cm 2 . Figure 5 shows the models of the QLED and the phantom that were used and the resulting fluence rate (mW/cm 2 ) along two cross sections of the phantom (these cross sections are indicated A and B in Fig. 5b) . The simulations suggest that the attenuation of the light emitted from a QLED will depend on the relative location within the device. Thus, the light power will attenuate to 60% of its maximum value in the middle of the phantom (line C, Fig. 5c ) and 30% of its maximum value in the middle of the light emitted square (line D, Fig. 5d ) at a depth of about 4 mm. In a laser-based PDTwith a 8 × 8 mm source, the light will attenuate to 35% of its maximum value at the center of the laser beam at a depth of 4 mm in the same phantom (data not shown).
The evaluation of 635-nm QLEDs for ALA-PpIX PDT and associated dosimetry of oral malignancies can be carried out using a combination of in-vitro 3D co-culture models and animal models of oral cancers. This work will build on the prior experience of the Celli group in development and evaluation of LED-based PDT sources, 9 but leveraging QLEDs as a uniquely efficient and flexible source for ergonomic light delivery to lesions on otherwise challenging surfaces within the oral cavity.
Overall, as envisioned in these specific examples, the QLED light source could provide an ideal platform for various photomedicine applications.
Potential impact
The demonstrations of ultrabright deep red QLEDs and their effectiveness for PBM and PDT warrant further studies investigating QLED devices for photomedical applications. We believe that this QLED-based technology, initially developed out of strong interests from information display industry, can make inroads into new medical areas, enable the widespread clinical application and acceptance of photomedicine (e.g. PDT and PBM) and have a direct, beneficial impact to mankind by radically changing the ways to manage cancer, acute and chronic wounds, inflammation and antimicrobial resistance among others, with an estimated annual market size of over $200 billions. 18, 19 The experience and knowledge gained in these developments could help enhance QLED stability and open up wider applications for QLEDs in display and lightings in the future. 
